Media stories about TESARO (NASDAQ:TSRO) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. TESARO earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.6355103093003 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

TSRO has been the subject of several research reports. Gabelli initiated coverage on shares of TESARO in a research report on Friday, July 7th. They set a “buy” rating and a $175.00 price target for the company. ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. initiated coverage on shares of TESARO in a research report on Thursday, May 25th. They set an “outperform” rating and a $183.00 price target for the company. Wedbush raised shares of TESARO to an “outperform” rating and set a $168.00 price target for the company in a research report on Monday, June 5th. Finally, Credit Suisse Group set a $198.00 price target on shares of TESARO and gave the company a “buy” rating in a research report on Wednesday, July 19th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. TESARO currently has a consensus rating of “Buy” and a consensus target price of $175.15.

Shares of TESARO (TSRO) opened at 115.63 on Thursday. TESARO has a 12 month low of $93.93 and a 12 month high of $192.94. The company has a 50-day moving average price of $122.82 and a 200-day moving average price of $141.29. The company’s market capitalization is $6.26 billion.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter in the previous year, the firm posted ($1.28) earnings per share. The firm’s revenue for the quarter was down 17.6% compared to the same quarter last year. On average, analysts forecast that TESARO will post ($8.67) EPS for the current fiscal year.

In related news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the sale, the vice president now directly owns 6,258 shares in the company, valued at $844,329.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Insiders have sold 25,100 shares of company stock valued at $3,387,465 over the last quarter. 34.60% of the stock is owned by company insiders.

WARNING: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at


TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.